High-dose influenza vaccine augments serological and cellular immunity of older people with HIV
JCI Insight · 22.04.2026 · 11 (8)
DOI: 10.1172/jci.insight.199232 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, online erschienen am 05.03.2026. Verfasst von Jonah Kupritz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology. Hauptthemen laut MEDLINE: Influenza Vaccines, HIV Infections, Influenza, Human, Immunity, Cellular. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIA NIH HHS, National Institute on Aging.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
BACKGROUND High-dose influenza vaccine, containing 4 times more antigen than the standard dose, is recommended for people 65 years or older, but there is a knowledge gap surrounding its effect in people with HIV (PWH), who remain more vulnerable to serious influenza infections than people without HIV (PWoH) despite virological suppression. Our primary goal was to assess whether the high-dose vaccine improves antibody responses in PWH, especially older PWH. METHODS We assessed antibody responses to sequential high- versus standard-dose influenza vaccination in PWH. Young (18–40 years) PWoH ( n = 55) and PWH ( n = 37) and older (≥60 years) PWoH ( n = 72) and PWH ( n = 67) received a standard-dose vaccine during the 2020–2024 seasons, and 123 participants (41 older PWH) received a high-dose vaccine the subsequent season. All PWH were virologically suppressed on antiretroviral therapy. HA inhibition (HAI) titer and HA-specific IgG were analyzed at 0 to 180 days after vaccination; T cell activation–induced responses were assessed by flow cytometry. RESULTS All groups mounted significant HAI and IgG responses to all vaccine antigens at 28 days after standard- and high-dose vaccination. Responses to A/H1N1 were lower in magnitude and durability in older PWH compared with young PWoH after the standard dose and were not boosted with the high dose, whereas the high dose enhanced A/H3N2 and B/Victoria IgG, in addition to CD4 + T cell responses to all antigens, in older PWH. CONCLUSION Our data demonstrate partial efficacy of a high-dose vaccine in augmenting antibody responses of older PWH while highlighting limitations in boosting A/H1N1-specific responses. TRIAL REGISTRATION ClinicalTrials.gov NCT04487041. FUNDING NIH grant (5R01AG068110).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology.
- Division of Biostatistics, Department of Public Health Sciences; and.
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Förderung
- NIAID NIH HHS
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Kupritz, J., Davis, S., Liu, T., Singh, P., Díaz-Pachón, D. A., Rodriguez, A., Boyd, S. D., Pahwa, R., Pallikkuth, S., & Pahwa, S. G. (2026). High-dose influenza vaccine augments serological and cellular immunity of older people with HIV. JCI Insight, 11(8). https://doi.org/10.1172/jci.insight.199232
Vancouver
Kupritz J, Davis S, Liu T, Singh P, Díaz-Pachón DA, Rodriguez A, et al. High-dose influenza vaccine augments serological and cellular immunity of older people with HIV. JCI Insight. 2026;11(8). doi:10.1172/jci.insight.199232
BibTeX
@article{Kupritz2026,
author = {Kupritz, Jonah and Davis, Sheldon and Liu, TianHao and Singh, Prabhsimran and Díaz-Pachón, Daniel Andrés and Rodriguez, Allan and Boyd, Scott D and Pahwa, Rajendra and Pallikkuth, Suresh and Pahwa, Savita G},
title = {High-dose influenza vaccine augments serological and cellular immunity of older people with HIV},
journal = {JCI Insight},
year = {2026},
volume = {11},
number = {8},
doi = {10.1172/jci.insight.199232}
}
EUVIMED